1-4 of 4
William J Edenfield, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 410.
https://doi.org/10.1182/blood.V130.Suppl_1.410.410
Published: 2017
Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD
Journal: Blood
Blood (2016) 128 (22): 4195.
https://doi.org/10.1182/blood.V128.22.4195.4195
Published: 2016
Journal Articles

CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

Anita K. Gandhi, PhD, Ribrag Vincent, MD, Cecilia Carpio, MD, Anne-Marie Stoppa, MD, Mecide Meric Gharibo, MD, Sylvia Damian, MD, Drew W Rasco, MD, Loïc Ysebaert, MDPhD, Raúl Cordoba, MD, Armando Santoro, MD, William J Edenfield, MD, Antonio Pinto, José Antonio López-Martín, MD, Juan Manuel Sancho, MD PhD, Carlos Panizo, PhD, Xin Wei, Patrick Hagner, PhD, Michelle Waldman, MS, Kristen Hege, Rajesh Chopra, MBBS, PhD, Michael Pourdehnad, MD
Journal: Blood
Blood (2015) 126 (23): 2704.
https://doi.org/10.1182/blood.V126.23.2704.2704
Published: 2015
Journal Articles

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Kevin R. Kelly, MD PhD, Nashat Y. Gabrail, MD, William J Edenfield, MD, A Craig Lockhart, Anthony J. Olszanski, MDPhD, Guru Reddy
Journal: Blood
Blood (2015) 126 (23): 3966.
https://doi.org/10.1182/blood.V126.23.3966.3966
Published: 2015